A groundbreaking moment from 2017— the FDA approval of Kymriah – St. Baldrick’s Foundation
St. Baldrick’s Foundation shared a post on LinkedIn:
“Today, we’re looking back on a groundbreaking moment from 2017— the FDA approval of Kymriah, the first gene therapy in the U.S. for kids with high-risk leukemia.
This life-saving treatment brought hope to kids like Austin. Diagnosed at 2 with acute lymphoblastic leukemia, Austin faced years of treatment, relapse, and a bone marrow transplant.
By 2013, his cancer had returned, leaving Kymriah as his last hope. Thanks to a St. Baldrick’s-supported clinical trial, Kymriah’s CAR T cells eradicated his cancer.
Now, Austin is 15, cancer-free, and thriving. He’s learning to drive, excelling in trap shooting, and dreaming of becoming a welder.
Kymriah represents hope for kids like Austin, and this hope begins with research — made possible by your support. Help support the next major childhood cancer breakthrough.”
Additional information.
Source: St. Baldrick’s Foundation/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023